SNAC | Jotup

Savory Snack Sales Surge 29% During Super Bowl Week 2023

Retrieved on:

화요일, 2월 6, 2024

Bowl game, Allegiant, Snack, Super Bowl, SNAC, Allegiant Stadium, Fast food

ARLINGTON, Va., Feb. 6, 2024 /PRNewswire/ -- Savory snack food sales jumped to $796 million during Super Bowl Week 2023, according to new data from Circana, commissioned by SNAC International (SNAC), the leading international trade association for the snack industry representing over 400 companies worldwide. The sales total represents a remarkable 29% increase from Super Bowl Week 2022.

Key Points:

The data reveals that Americans consumed 118 million pounds of savory snacks during the latest Super Bowl Week.
"Every brand wants to be the go-to Super Bowl snack, just like every fan wants their team to win the Super Bowl."
Super Bowl week ranks #1 in terms of total snack sales for the entire year.
The sales numbers for Super Bowl Week 2023 in dollar value, percent increase from 2022, and pounds sold are as follows:
For more information about snack sales and SNAC International, please visit https://snacintl.org/ .

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on:

수요일, 1월 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points:

GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on:

수요일, 1월 10, 2024

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points:

GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on:

월요일, 1월 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points:

GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on:

월요일, 1월 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points:

GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Spoke Sciences Acquires “SNAC” Drug Delivery Platform that Improves Bioavailability of Nutritional Supplements and Drugs

Retrieved on:

화요일, 7월 25, 2023

Retail, Health, Fitness & Nutrition, General Health, Pharmaceutical, Food, Beverage, Biotechnology, Drink, Cosmetics, SNAC, Biopharmaceutics Classification System, Science, B-12, BCS, Fine chemical, Pharmaceutical industry, Spoke

Spoke has acquired from Seattle-based Receptor Life Sciences a patent portfolio covering the use of SNAC with certain non-water-soluble, e.g., “lipophilic” active ingredients.

Key Points:

Spoke has acquired from Seattle-based Receptor Life Sciences a patent portfolio covering the use of SNAC with certain non-water-soluble, e.g., “lipophilic” active ingredients.
Because many pharmaceutical and naturally occurring compounds used in drugs, supplements and functional foods are BCS Class II, SNAC has tremendous potential.
Spoke Sciences is an ingredient technology company developing innovative approaches to provide better, safer, and more reliable functional ingredients to foods, beverages, and cosmetics.
For more information about Spoke Sciences, its patented technologies and exciting new consumer products, visit: www.spokesciences.com .

SNAC International Releases 2023 State of the Industry Report

Retrieved on:

수요일, 5월 24, 2023

Food, Snack, Tax revenue, Game Industry Report Magazine, IRI, Growth, SNAC, Fast food

ARLINGTON, Va., May 24, 2023 /PRNewswire/ -- SNAC International, the leading nonprofit, snack-centric trade association, announces the release of its "2023 State of the Industry Report", in a special edition of their annual magazine SNAC World. The report highlights key insights and emerging trends shaping the future of this dynamic sector.

Key Points:

Snacking Makes a Big Impact Employing 395,000, Generating $15 Billion in Wages and $11 Billion in Tax Revenue
ARLINGTON, Va., May 24, 2023 /PRNewswire/ -- SNAC International, the leading nonprofit, snack-centric trade association, announces the release of its " 2023 State of the Industry Report", in a special edition of their annual magazine SNAC World.
"I am especially proud of the work to define the economic impact of the snack industry", says Cochran, CEO, SNAC International.
The "2023 State of the Industry Report," brought together by Circana (previously IRI) and Sosland Publishing, takes a deep dive into the latest industry trends, sales/unit data, new product innovation, and insights from leading industry innovators.
The full report including category-specific sales data can be downloaded here: SNAC World's Official State of the Industry Report .

Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes

Retrieved on:

금요일, 1월 13, 2023

This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes.

Key Points:

This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes.
"By taking Rybelsus® first, people with type 2 diabetes, in conjunction with their care teams, are now able to utilize this medicine early in their diabetes treatment journeys."
Novo Nordisk works with health insurance providers to ensure broad insurance coverage and patient access to Rybelsus®.
Eligible, commercially insured patients may pay as little as $10 for a one- to three-month prescription of this medicine.

iconectiv Toll-Free-Number Expert Mike Gilbert Elected ATIS SNAC Co-Chair

Retrieved on:

목요일, 4월 21, 2022

The SMS/800 Number Administration Committee (SNAC) leads industry initiatives involving toll-free numbers, such as enabling text messaging, providing guidance for database administration and advising the FCC.

Key Points:

The SMS/800 Number Administration Committee (SNAC) leads industry initiatives involving toll-free numbers, such as enabling text messaging, providing guidance for database administration and advising the FCC.
Part of the Alliance for Telecommunications Industry Solutions (ATIS), SNAC is uniquely positioned to help ensure the integrity of toll-free numbers and their effectiveness as a communications channel.
iconectiv Senior Account Director Mike Gilbert has been named SNAC co-chair for a two-year term.
Through Gilberts leadership, SNAC will additionally benefit from iconectivs expertise in mitigating illegal robocalls, SMS phishing (smishing), wangiri callback schemes and other fraud.

SNAC International Announces SNAC Tank and Audience Vote Winners

Retrieved on:

목요일, 4월 14, 2022

ARLINGTON, Va., April 14, 2022 /PRNewswire/ -- SNAC International's inaugural SNX 2022, the snack industry's education and networking forum, announced the winners of the second biennial "SNAC Tank," a pitch competition for start-up snack brands. The caliber of finalists challenged the audience and the panel of judges with innovative products and solid brand pitches.

Key Points:

NAC International's inaugural SNX 2022 announced the winners of the second biennial "SNAC Tank," Candid and Pulp Pantry.
Pulp Pantry , a brand of veggie chips made with upcycled, fresh vegetable juice pulp, took home the Audience Choice Award, which was decided via a live vote by the SNAC Tank crowd.
I want to congratulate both of our winners and look forward to seeing a new collection of innovative ideas for the next SNAC Tank."
Sponsored by SNAC International, the biennial SNX Education and Networking Forum offers venues for private business meetings between producers and suppliers.